We are delighted to announce that Chimera Bioengineering is the latest company to join the Kairos portfolio.

Founded in 2015,  Chimera Bioengineering is a biotherapeutics company building RNA based gene regulatory systems for chimeric antigen receptor CAR-T cell therapeutics with greater efficacy against solid tumors and superior safety. Co-founded by renowned synthetic biologist, Professor Christina Smolke, of Stanford University, Chimera leverages the combination of synthetic biology and immunotherapy, to widen therapeutic windows, expand treatment to cancers with unmet needs and create therapies that restore and maintain patient dignity. Chimera’s differentiated RNA based technologies enable conditional, real-time control over CAR-T, solving the critical challenges of safety and potency while extending persistence and efficacy. Chimera is a resident at JnJ’s prestigious JLABS incubator in South San Francisco and has the support of StartX, the Stanford affiliated accelerator and Illumina Accelerator.

“We are excited to partner with Kairos to advance Chimera’s technology platforms and product programs, combining synthetic biology and immuno-oncology, to bring more effective and safer CAR-T therapeutics to cancer patients.”
– Ben Wang, CEO of Chimera Bioengineering

With the funding provided by Kairos, Chimera will continue their development of control mechanisms for CAR-T cancer therapy. “We are excited to partner with Kairos to advance Chimera’s technology platforms and product programs, combining synthetic biology and immuno-oncology, to bring more effective and safer CAR-T therapeutics to cancer patients,” says Ben Wang, CEO of Chimera. “Kairos’ track record and expertise in enabling and growing cutting edge hard-technology driven companies makes them an ideal partner for Chimera.”

We are thrilled about our investment in Chimera Bioengineering and welcome them to the extended Kairos Ventures family!